V. A. Vavilin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
V. A. Vavilin has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
V. V. Lyakhovich
Siberian Branch of the Russian Academy of Medical Sciences
5 shared publicationsA. V. Kudryashov
Siberian Branch of the Russian Academy of Medical Sciences
2 shared publicationsD. L. Nepomnyashchikh
Siberian Division of the Russian Academy of Medical Sciences
1 shared publicationE. G. Shchepotina
Siberian Branch of the Russian Academy of Medical Sciences
1 shared publicationE. M. Stakhneva
Russian Academy of Medical Sciences
1 shared publicationE. V. Vinogradova
Siberian Division of the Russian Academy of Medical Sciences
1 shared publication
Latest Publications
- 13 December 2013
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 156 (2) , 181-184
Cytochrome P450 4F2 Polymorphism in Patients with Liver Cirrhosis
1297C/T polymorphism of CYP4F2 gene was studied in 108 patients with chronic liver diseases. No significant correlation with predisposition to rapid liver cirrhosis was revealed without consideration for cirrhosis etiology (OR = 0.93, 95% CI = 0.28-2.99, p = 0.885). In patients with viral cirrhosis, a tendency to association of 1297T allele genotypes with rapid cirrhosis development was found (OR = 6.0, 95% CI = 0.28-382.64, p = 0.222). At the same time, CYP4F2 1297T allele was associated with mild (Child–Pugh class A-B) cirrhosis (OR = 2.9, p = 0.044).
- 13 December 2013
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 156 (2) , 181-184
Cytochrome P450 4F2 Polymorphism in Patients with Liver Cirrhosis
1297C/T polymorphism of CYP4F2 gene was studied in 108 patients with chronic liver diseases. No significant correlation with predisposition to rapid liver cirrhosis was revealed without consideration for cirrhosis etiology (OR = 0.93, 95% CI = 0.28-2.99, p = 0.885). In patients with viral cirrhosis, a tendency to association of 1297T allele genotypes with rapid cirrhosis development was found (OR = 6.0, 95% CI = 0.28-382.64, p = 0.222). At the same time, CYP4F2 1297T allele was associated with mild (Child–Pugh class A-B) cirrhosis (OR = 2.9, p = 0.044).
- 13 October 2011
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 151 (6) , 741-746
Relationship between CYP2E1 Polymorphism and Increase of ALT Activity during Therapy of Patients with Pulmonary Tuberculosis
- 13 October 2011
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 151 (6) , 741-746
Relationship between CYP2E1 Polymorphism and Increase of ALT Activity during Therapy of Patients with Pulmonary Tuberculosis
- 9 November 2008
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry
- Vol. 2 (4) , 373-380
The cholesterol lowering properties of the complex compound simvastatin with glycyrrhizic acid (simvaglyzin) in experimental models
A molecular complex of simvastatin (SV) and glycyrrhizic acid (GA) (at their ratio of 1 : 4) has been synthesized. The complex named “simvaglyzin” (SVG) was stable in aqueous and aqueous-alcohol solutions at GA concentrations exceeding 0.2 mM. In vitro SVG acted as an uncompetitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA (3-HMG-CoA) reductase (Ki of 94 nM). Appearance of this inhibitory activity is associated with cytochrome P450-dependent conversion of SVG, because the addition of 1 mM metyrapone to the incubation medium fully prevented the inhibition of 3-HMG-CoA reductase. SV and SVG (used at 300 nM concentration) inhibited mevalonate synthesis rate by 39.15±8,27 and 38.85±3,04%, respectively. In vivo SVG showed a dose-dependent cholesterol lowering effect. In rats the cholesterol lowering effect of SVG used at daily doses equivalent to 66 and 100 mg/kg of SV was the same as the effect of SV administered at the daily dose of 200 mg/kg. The decrease in total cholesterol of blood serum was 7% and 9% (p < 0.05) and 8%, respectively. Myotoxicity of these SVG doses estimated by blood serum creatine phosphokinase (CPK) activity was lower than that of SV. In rats treated with SV the activity of CPK increased by 79% (p < 0.01), while in SVG treated rats it decreased by 30% and 36% (p < 0.05). Any increase of the hepatotoxicity markers alanine aminotransferase or aspartate aminotransferase in blood serum was not observed. The data suggest pharmacological synergism attributed to the SV-GA complex formation and increased safety of the resultant complex compared with a parent compound.
- 9 November 2008
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry
- Vol. 2 (4) , 373-380
The cholesterol lowering properties of the complex compound simvastatin with glycyrrhizic acid (simvaglyzin) in experimental models
A molecular complex of simvastatin (SV) and glycyrrhizic acid (GA) (at their ratio of 1 : 4) has been synthesized. The complex named “simvaglyzin” (SVG) was stable in aqueous and aqueous-alcohol solutions at GA concentrations exceeding 0.2 mM. In vitro SVG acted as an uncompetitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA (3-HMG-CoA) reductase (Ki of 94 nM). Appearance of this inhibitory activity is associated with cytochrome P450-dependent conversion of SVG, because the addition of 1 mM metyrapone to the incubation medium fully prevented the inhibition of 3-HMG-CoA reductase. SV and SVG (used at 300 nM concentration) inhibited mevalonate synthesis rate by 39.15±8,27 and 38.85±3,04%, respectively. In vivo SVG showed a dose-dependent cholesterol lowering effect. In rats the cholesterol lowering effect of SVG used at daily doses equivalent to 66 and 100 mg/kg of SV was the same as the effect of SV administered at the daily dose of 200 mg/kg. The decrease in total cholesterol of blood serum was 7% and 9% (p < 0.05) and 8%, respectively. Myotoxicity of these SVG doses estimated by blood serum creatine phosphokinase (CPK) activity was lower than that of SV. In rats treated with SV the activity of CPK increased by 79% (p < 0.01), while in SVG treated rats it decreased by 30% and 36% (p < 0.05). Any increase of the hepatotoxicity markers alanine aminotransferase or aspartate aminotransferase in blood serum was not observed. The data suggest pharmacological synergism attributed to the SV-GA complex formation and increased safety of the resultant complex compared with a parent compound.
- 1 October 2008
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 146 (4) , 420-423
Study of Polymorphic Variants C190T, G191A, G857A, and 859Del of the NAT2 Gene by the Method of Restriction Fragment Length Polymorphism
- 1 October 2008
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 146 (4) , 420-423
Study of Polymorphic Variants C190T, G191A, G857A, and 859Del of the NAT2 Gene by the Method of Restriction Fragment Length Polymorphism
- 1 April 2005
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 139 (4) , 431-433
Glutathione-S-Transferase Polymorphism and Clinical Features of Acute Drug Poisoning in Children
- 1 April 2005
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 139 (4) , 431-433
Glutathione-S-Transferase Polymorphism and Clinical Features of Acute Drug Poisoning in Children